| abstract |
The present disclosure relates to methods, systems, and kits for the diagnosis, prognosis, and determination of the course of prostate cancer in a subject. In particular, the present disclosure relates to the use of gene expression specific for immune cells to determine prognosis and to identify individuals in need of treatment for prostate cancer who will be sensitive to radiotherapy. |